Three months later, the joint inflammatory syndrome improved clinically/biologically and the joint discomfort and swelling partially subsided (the following results were obtained: CRP: 6.8 mg/L, DAS 28: 2.1, ESR: 29 mm/h, VAS: 22, SJC: 2, TJC: 3), but frequent infections at the respiratory level and severe dyspnea occurred, requiring antibiotics (i.e., levofloxacin, 750 mg IV daily for 10 days, 3 episodes of infection in 3 months) and salbutamol nebulizer treatment. This evidence concerns the gene CRP and infection.